Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 16;12(2):378–392. doi: 10.1002/jcsm.12680

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Plasma tissue inhibitor of metalloproteinases‐1 (TIMP‐1) levels differentiate subpopulations of weight loss (WL)‐defined cachectic colorectal cancer (CRC) patients. Survival of CRC patients (n = 80) separated by relative WL (A). Correlation of plasma TIMP‐1 levels with relative WL of CRC patients (n = 82) (B). Survival of CRC patients with increased WL (WL^HI, n = 34) separated by plasma TIMP‐1 levels (C, cut‐off: 288.37 ng/mL TIMP‐1). Hazard ratios (HRs) are shown including the corresponding 95.0% confidence interval (A, C). Relative WL of WL^HI CRC patients separated by plasma TIMP‐1 levels is shown as individual dots and medians with interquartile range (D).